Susquehanna International Group, LLP Navidea Biopharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	SELL	$0.72 - $1.2 $14,472 - $24,120	-20,100 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.0 - $1.82 $13,500 - $24,570	-13,500 Reduced 40.18%	20,100 $20,000
Q3 2021 Nov 15, 2021	SELL	$1.53 - $1.85 $73,746 - $89,170	-48,200 Reduced 58.92%	33,600 $59,000
Q2 2021 Aug 11, 2021	BUY	$1.55 - $2.15 $16,585 - $23,005	10,700 Added 15.05%	81,800 $150,000
Q1 2021 May 17, 2021	BUY	$1.99 - $2.9 $11,940 - $17,400	6,000 Added 9.22%	71,100 $144,000
Q4 2020 Feb 16, 2021	SELL	$1.88 - $2.84 $126,336 - $190,848	-67,200 Reduced 50.79%	65,100 $140,000
Q3 2020 Nov 16, 2020	BUY	$2.69 - $4.95 $243,983 - $448,965	90,700 Added 218.03%	132,300 $357,000
Q2 2020 Aug 14, 2020	BUY	$0.7 - $4.16 $15,259 - $90,688	21,800 Added 110.1%	41,600 $164,000
Q1 2020 May 15, 2020	SELL	$0.76 - $1.54 $18,316 - $37,114	-24,100 Reduced 54.9%	19,800 $15,000
Q4 2019 Feb 14, 2020	BUY	$0.65 - $1.26 $16,705 - $32,382	25,700 Added 141.21%	43,900 $55,000
Q3 2019 Nov 14, 2019	BUY	$0.5 - $0.91 $9,100 - $16,562	18,200 New	18,200 $13,000

10.4K

Ticker NAVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,150,900
Description
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expr...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.